Press Releases - G1 Therapeutics, Inc.

Press Releases

Date	Title
6/1/22	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/20/22	G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal
5/18/22	G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
5/4/22	G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights
5/2/22	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/21/22	G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022
4/6/22	G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
4/1/22	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/31/22	New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Chemotherapy
3/1/22	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)